Legend Biotech

Company Legal / IP

GenScript Biotech Sues Former CSO Fan Xiaohu for Trade Secret Infringement

Fineline Cube Aug 18, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has sued its former...

Company

GenScript’s Legend Biotech Appoints Three New Directors to Board

Fineline Cube Aug 5, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...

Company Deals

Legend Biotech Plans USD 250M Secondary Offering to Fund CAR-T Therapy Development

Fineline Cube Jul 26, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell...

Company Drug

GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial

Fineline Cube Jul 8, 2022

Hong Kong-based GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ:...

Company Deals R&D

Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors

Fineline Cube Jun 29, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and...

Company Drug

China Medical System’s Silvemimab Becomes World’s First Dual-Epitope Fully Human Rabies Antibody Approved in China

Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Company Drug

Biokin Secures World’s First EGFR×HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma

Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted